Randomized trial demonstrates prolonged survival with sorafenib in advanced hepatocellular carcinoma, highlighting a new systemic treatment option.
In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)
No takes yet. Share an insight, caveat, or question.
Llovet et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: